CCL2, C-C motif chemokine ligand 2, 6347

N. diseases: 1157; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE A tendency to increase the inflammatory markers IL-6 (p = 0.069) and MCP-1 (p = 0.067) was observed in those patients suffering from MS. An increase in the cardiovascular risk markers PAI-1 (p = 0.007) and triglycerides/HDL cholesterol ratio (p < 0.0001) was also found in the MS group. 30924020 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 AlteredExpression disease BEFREE Comparison of gene expression pattern between CAD and MetS revealed significantly higher expression of leukotriene genes - arachidonate 5-lipoxygenase (ALOX5), arachidonate 5-lipoxygenase activating protein (ALOX5 AP), leukotriene A4 hydrolase (LTA4H) and leukotriene C4 synthase (LTC4S), and lower expression of NF-κB, interleukin 1 beta (IL-1β), monocyte chemoattractant protein-1 (MCP-1/CCL2) and signal transducer and activator of transcription 3 (STAT3) genes in CAD. 29067980 2017
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE MCP-1 allele and genotype were significantly associated with MetS. 25639755 2015
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE In addition to increased expression of downstream signaling mediators RIPK2 and NF-κB p65 nuclear translocation, there was remarkably higher release of monocyte chemotactic protein1 (MCP-1), interleukin (IL)-6, and IL-8 in MetS versus controls following priming of the isolated adipocytes with NOD1 ligand iE-DAP. 26052894 2015
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE FAM5C also corresponds directly with the inflammatory biomarker monocyte chemoattractant protein 1 (MCP-1) and metabolic syndrome. 22013132 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE Serum MCP-1 (P = 0·02), eotaxin-1 (P = 0·02) and MIP-1β (P = 0·03), CRP (P < 0·001) and IL-6 (P = 0·006) were significantly increased in metabolic syndrome in comparison with lean controls. 23170936 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE Neutralization of the pro-inflammatory pathway Fas/FasL completely prevented vascular hypo-reactivity and the ability of MetS microparticles to enhance both inducible NO-synthase and monocyte chemoattractant protein-1 (MCP-1). 22110764 2011
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 GeneticVariation disease BEFREE The MCP-1 -2518G allele may be contributing to atherosclerosis and CAD by conferring an increased risk to metabolic syndrome and/or obesity. 19450143 2009
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 AlteredExpression disease BEFREE Enhanced levels of MCP1 resulting from reduced IRS2 expression and accompanying defects in AKT2 and Ras/ERK1/2 signaling pathways may contribute to accelerated atherosclerosis in MetS states. 18802016 2008
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease CTD_human Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients? 18486454 2008
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease BEFREE This is the first study to investigate the associations of MCP-1 SNPs with MetS. 17322498 2007
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.400 Biomarker disease CTD_human This paradigm supports the notion that elevated CCL2 levels in visceral adipose tissue associated with Metabolic Syndrome is a chemotactic niche, whereby fibrocytes can home to and differentiate into adipocytes to perpetuate its tissue formation. 16188961 2005